The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

“This study suggests that there is no protective (or harmful) association of memantine [a second-line drug for dementia] or donepezil [a first-line drug] with the risk of developing age-related ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

In the retina, age-related macular degeneration (AMD) affects the complex of photoreceptors, retinal pigment epithelium (RPE), Bruch’s membrane (BM) and the choriocapillaris, the innermost layer of ...

Age-related macular degeneration (AMD) is the leading cause of visual impairment in people over age 50 years. It affects the macula, the central part of the retina responsible for sharp vision. There ...

A study supported the ellipsoid zone loss as a meaningful biomarker that can be used to guide clinical trial design in ...

HealthDay News — The Pooled Cohort Equations (PCE) cardiovascular risk score stratifies risk for multiple ocular diseases, according to a study published online Dec. 29 in Ophthalmology.

– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...

Age-related macular degeneration (AMD) gradually affects central vision in one or both eyes while leaving peripheral vision (on the sides) intact. This peripheral vision – encompassing everything you ...

FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on ...

The age-related macular degeneration (AMD) market in the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK ...